Boi M et al.Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes.Oncotarget 7:79637-79653 (2016).
Coudé MM et al.BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells.Oncotarget 6:17698-712 (2015).
Thompson CM et al.Critical assessment of influenza VLP production in Sf9 and HEK293 expression systems.BMC Biotechnol 15:31 (2015).
Boi M et al.The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs.Clin Cancer Res 21:1628-38 (2015).
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"